P P M M Geusens

Summary

Affiliation: University Hospital
Country: Belgium

Publications

  1. doi request reprint Strategies for treatment to prevent fragility fractures in postmenopausal women
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Best Pract Res Clin Rheumatol 23:727-40. 2009
  2. ncbi request reprint Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Centre, P Debyelaan 25, Maastricht, The Netherlands
    Curr Osteoporos Rep 7:12-7. 2009
  3. ncbi request reprint Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD)
    Piet Geusens
    University Hasselt, University Hospital, The Netherlands
    Expert Opin Biol Ther 9:649-57. 2009
  4. doi request reprint Fracture prevention in men
    Piet Geusens
    Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Nat Rev Rheumatol 5:497-504. 2009
  5. pmc The P2X(7) loss-of-function Glu496Ala polymorphism affects ex vivo cytokine release and protects against the cytotoxic effects of high ATP-levels
    Anke Wesselius
    Department of Epidemiology, Maastricht University, School for Public Health and Primary Care CAPHRI, Peter Debyeplein 1, Maastricht, MD 6200, The Netherlands
    BMC Immunol 13:64. 2012
  6. doi request reprint NSAIDs and fracture healing
    Piet Geusens
    Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Curr Opin Rheumatol 25:524-31. 2013
  7. doi request reprint Bone: New guidelines for multistep fracture prevention in men
    Piet P M Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Centre, P O Box 616, 6200 MD Maastricht, The Netherlands
    Nat Rev Rheumatol 8:568-70. 2012
  8. pmc Osteoimmunology and osteoporosis
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, P, Debyelaan 25 Postbus 5800, 6202 AZ Maastricht, The Netherlands
    Arthritis Res Ther 13:242. 2011
  9. pmc Assessment of individual fracture risk: FRAX and beyond
    Joop P W van den Bergh
    Department of Internal Medicine, VieCuri Medical Centre Noord Limburg, PO Box 1926, 5900 BX Venlo, The Netherlands
    Curr Osteoporos Rep 8:131-7. 2010
  10. pmc Optimal use of vitamin D when treating osteoporosis
    Joop P W van den Bergh
    Department of Internal Medicine, VieCuri Medical Centre Noord Limburg, PO Box 1926, 5900 BX, Venlo, The Netherlands
    Curr Osteoporos Rep 9:36-42. 2011

Collaborators

Detail Information

Publications45

  1. doi request reprint Strategies for treatment to prevent fragility fractures in postmenopausal women
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Best Pract Res Clin Rheumatol 23:727-40. 2009
    ..Follow-up allows to check tolerance and safety, to optimise adherence and to decide about adequacy of response, duration and switching of therapy...
  2. ncbi request reprint Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Centre, P Debyelaan 25, Maastricht, The Netherlands
    Curr Osteoporos Rep 7:12-7. 2009
    ..However, the usefulness of more than 5 years of treatment with BPs needs to be proved with higher levels of evidence-based medicine...
  3. ncbi request reprint Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD)
    Piet Geusens
    University Hasselt, University Hospital, The Netherlands
    Expert Opin Biol Ther 9:649-57. 2009
    ..AZD3582 (Naproxcinod) is the first in the class of CINODs...
  4. doi request reprint Fracture prevention in men
    Piet Geusens
    Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Nat Rev Rheumatol 5:497-504. 2009
    ..For men with severe osteoporosis, treatment with the anabolic agent teriparatide might be an effective option...
  5. pmc The P2X(7) loss-of-function Glu496Ala polymorphism affects ex vivo cytokine release and protects against the cytotoxic effects of high ATP-levels
    Anke Wesselius
    Department of Epidemiology, Maastricht University, School for Public Health and Primary Care CAPHRI, Peter Debyeplein 1, Maastricht, MD 6200, The Netherlands
    BMC Immunol 13:64. 2012
    ..Therefore, we investigated whether a known loss-of-function polymorphism (Glu496Ala) in the P2X(7) receptor gene leads to alterations in cytokine release in response to ATP...
  6. doi request reprint NSAIDs and fracture healing
    Piet Geusens
    Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Curr Opin Rheumatol 25:524-31. 2013
    ..However, clinical reports on the effect of COX-2 inhibition on fracture healing in humans have been variable and inconclusive. This review gives an overview of the published data and an advice when to avoid NSAIDs...
  7. doi request reprint Bone: New guidelines for multistep fracture prevention in men
    Piet P M Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Centre, P O Box 616, 6200 MD Maastricht, The Netherlands
    Nat Rev Rheumatol 8:568-70. 2012
    ..Guidelines from the Endocrine Society for the management of osteoporosis and fracture risk in men are thus welcome, but further research into fracture prevention in men is required...
  8. pmc Osteoimmunology and osteoporosis
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, P, Debyelaan 25 Postbus 5800, 6202 AZ Maastricht, The Netherlands
    Arthritis Res Ther 13:242. 2011
    ..With the availability of new techniques to evaluate peri-inflammatory bone loss, osteitis, and erosions, peri-inflammatory bone changes are an exciting field for further research in the context of osteoimmunology...
  9. pmc Assessment of individual fracture risk: FRAX and beyond
    Joop P W van den Bergh
    Department of Internal Medicine, VieCuri Medical Centre Noord Limburg, PO Box 1926, 5900 BX Venlo, The Netherlands
    Curr Osteoporos Rep 8:131-7. 2010
    ..FRAX may be used as the primary model, and in patients with recurrent fractures and falls the use of the Garvan model may be of additional value...
  10. pmc Optimal use of vitamin D when treating osteoporosis
    Joop P W van den Bergh
    Department of Internal Medicine, VieCuri Medical Centre Noord Limburg, PO Box 1926, 5900 BX, Venlo, The Netherlands
    Curr Osteoporos Rep 9:36-42. 2011
    ..Monitoring of 25(OH)D levels during follow-up and adjustment of vitamin D supplementation should be considered to reach and maintain adequate serum 25(OH)D levels of at least 50 nmol/L, preferably greater than 75 nmol/L in all patients...
  11. pmc Timing of subsequent fractures after an initial fracture
    Tineke A C M van Geel
    Department of General Practice, Maastricht University Caphri, PO Box 616, 6200 MD Maastricht, The Netherlands
    Curr Osteoporos Rep 8:118-22. 2010
    ..These studies indicate the need for early action after an initial fracture with medical interventions that have an effect within a short term to reduce the preventable risks of subsequent fractures...
  12. pmc Risk of falling in patients with a recent fracture
    Svenhjalmar van Helden
    Department of General Surgery Traumatology, University Hospital Maastricht, Maastricht, The Netherlands
    BMC Musculoskelet Disord 8:55. 2007
    ..The aim of this study was to assess the number of patients with falls and to identify fall risk factors that predict the risk of falling in the first three months after a clinical fracture...
  13. pmc Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach
    Bianca Dumitrescu
    Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands
    BMC Musculoskelet Disord 9:109. 2008
    ..Identifying and correcting these associated disorders will enhance treatment effect aimed at reducing the risk of subsequent fractures in patients older than 50 years...
  14. pmc Timing and risk factors for clinical fractures among postmenopausal women: a 5-year prospective study
    Antonia C M van Geel
    Care and Public Health Research Institute, Department of General Practice, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands
    BMC Med 4:24. 2006
    ..Therefore, we assessed the risk and timing of incident clinical fractures, expressed as 5-year AR, in postmenopausal women...
  15. pmc Progress in osteoporosis and fracture prevention: focus on postmenopausal women
    Kenneth G Saag
    Division of Clinical Immunology and Rheumatology, Center for Education and Research on Therapeutics, University of Alabama at Birmingham, 820 Faculty Office Tower, 510 20th Street South, Birmingham, AL 35294 3708, USA
    Arthritis Res Ther 11:251. 2009
    ..Emerging therapeutic options that target molecules of bone metabolism indicate that the next decade should offer even greater promise for further improving our diagnostic and treatment approaches...
  16. ncbi request reprint Osteoporosis: clinical features
    P Geusens
    Internal Medicine and Rheumatology, University Hospital, Maastricht, The Netherlands
    Minerva Med 99:167-75. 2008
    ..In addition, many patients with fractures and osteoporosis have pre-existing contributors to secondary osteoporosis, many of which are correctable...
  17. ncbi request reprint [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid]
    P P M M Geusens
    Academisch Ziekenhuis Maastricht, afd Interne Geneeskunde Reumatologie, Postbus 5800, 6202 AZ Maastricht
    Ned Tijdschr Geneeskd 151:1445-8. 2007
    ..Some examples of candidates for treatment with zoledronic acid would be patients with osteoporosis in whom oral treatment meets objections or who are hospitalised due to a fracture...
  18. doi request reprint Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective
    Piet P Geusens
    Department of Internal Medicine, Division of Rheumatology, University Hospital, P Debyelaan 25, Box 5800, 6202 AZ Maastricht, The Netherlands
    Nat Clin Pract Rheumatol 4:240-8. 2008
    ..Other determinants include the potential extraskeletal benefits and safety concerns of the drug, patient preferences and reimbursement issues...
  19. pmc Emerging treatments for postmenopausal osteoporosis - focus on denosumab
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Clin Interv Aging 4:241-50. 2009
    ....
  20. doi request reprint Impact of systematic implementation of a clinical case finding strategy on diagnosis and therapy of postmenopausal osteoporosis
    Piet Geusens
    Biomedical Research Institute, University Hasselt, Hasselt, Belgium
    J Bone Miner Res 23:812-8. 2008
    ..We studied, in daily practice, the impact of systematic implementation of a previously validated clinical decision rule and fracture history on referral for bone densitometry (DXA) and drug prescription for osteoporosis...
  21. ncbi request reprint Integrating a gender dimension into osteoporosis and fracture risk research
    Piet Geusens
    Department of Internal Medicine Rheumatology, University Hospital, Maastricht, The Netherlands
    Gend Med 4:S147-61. 2007
    ..Sex (referring to the strict biological sense) and gender (referring to the sociocultural dimension) are major determinants of health and disease...
  22. ncbi request reprint Newer drug treatments: their effects on fracture prevention
    Piet Geusens
    Biomedical Research Institute, University Hasselt, Campus Diepenbeek, Belgium
    Best Pract Res Clin Rheumatol 19:983-9. 2005
    ..Some new drugs that are being studied for their potential anti-fracture effects are listed...
  23. ncbi request reprint Osteoporosis and vertebral fractures in ankylosing spondylitis
    Piet Geusens
    Division of Rheumatology, Department of Internal Medicine, University Hospital Maastricht, The Netherlands
    Curr Opin Rheumatol 19:335-9. 2007
    ..To review recent data, in the context of what is already known, about an increased risk of vertebral fractures in ankylosing spondylitis patients...
  24. ncbi request reprint The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction
    P P Geusens
    University Hospital, Maastricht, The Netherlands
    Arthritis Rheum 54:1772-7. 2006
    ....
  25. ncbi request reprint Review and evaluation of the Dutch guidelines for osteoporosis
    Piet P Geusens
    Department of Rheumatology, University Hospital, Maastricht, The Netherlands
    J Eval Clin Pract 12:539-48. 2006
    ..These guidelines were evaluated for their validity and applicability...
  26. ncbi request reprint The relationship among history of falls, osteoporosis, and fractures in postmenopausal women
    Piet Geusens
    Biomedical Research Institute, Limburgs Universitair Centrum, Diepenbeek, Belgium
    Arch Phys Med Rehabil 83:903-6. 2002
    ..To study the relative contribution of osteoporosis and falls to the occurrence of symptomatic fractures in postmenopausal women...
  27. ncbi request reprint Bone turnover and hip bone mineral density in patients with sarcoidosis
    A Caroline Heijckmann
    Department of Internal Medicine, Division of Endocrinology, University Hospital Maastricht, The Netherlands
    Sarcoidosis Vasc Diffuse Lung Dis 24:51-8. 2007
    ..We evaluated bone remodelling and bone mineral density (BMD) in patients with sarcoidosis and their dependency of disease-related and treatment-related factors...
  28. ncbi request reprint Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma
    A Caroline Heijckmann
    Department of Internal Medicine, Division of Endocrinology, University Hospital Maastricht, Maastricht, The Netherlands
    Eur J Endocrinol 153:23-9. 2005
    ..However, their effect on bone turnover, their contribution to bone mineral density (BMD) in the context of other clinical risk factors for osteoporosis and the prevalence of vertebral fractures is not well documented...
  29. doi request reprint High prevalence of morphometric vertebral deformities in patients with inflammatory bowel disease
    Anna Caroline Heijckmann
    Department of Internal Medicine, Division of Endocrinology, Hospital Bernhoven, Veghel, The Netherlands
    Eur J Gastroenterol Hepatol 20:740-7. 2008
    ..The objective of this study was to investigate the prevalence of vertebral deformities in inflammatory bowel disease patients and their relation with BMD and bone turnover...
  30. ncbi request reprint Performance of risk indices for identifying low bone density in postmenopausal women
    Piet Geusens
    Biomedical Research Institute, Limburg University, Diepenbeek, Belgium
    Mayo Clin Proc 77:629-37. 2002
    ..To examine the ability of 4 published osteoporosis risk indices to identify women with low bone density...
  31. ncbi request reprint Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)
    Desiree van der Heijde
    University Hospital Maastricht, Maastricht, The Netherlands
    Arthritis Rheum 52:582-91. 2005
    ..The objective of this multicenter, randomized, placebo-controlled study was to evaluate the efficacy and safety of infliximab in patients with AS...
  32. ncbi request reprint Clinical vertebral fractures in patients with ankylosing spondylitis
    Debby Vosse
    Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
    J Rheumatol 31:1981-5. 2004
    ..To evaluate the prevalence and characteristics of clinically confirmed vertebral fractures (CVF) in patients with ankylosing spondylitis (AS)...
  33. ncbi request reprint Falls and fractures in postmenopausal women: a review
    Piet Geusens
    Biomedical Research Institute, Limburgs Universitair Centrum, Diepenbeek, Belgium
    J Br Menopause Soc 9:101-6. 2003
    ..Prospective studies are needed to evaluate whether a combined bone- and fall-directed therapy can further decrease the risk for fractures in patients with low bone density and an increased fall risk...
  34. ncbi request reprint Factors affecting bone loss in female endurance athletes: a two-year follow-up study
    Lavienja A J L M Braam
    Department of Biochemistry, University of Maastricht, Maastricht, The Netherlands
    Am J Sports Med 31:889-95. 2003
    ..Low bone mass leading to stress fractures is a well-known and yet unsolved problem among female athletes...
  35. pmc Quantitative ultrasound does not identify patients with an inflammatory disease at risk of vertebral deformities
    A Caroline Heijckmann
    Department Internal Medicine, Division of Endocrinology, University Hospital Maastricht, The Netherlands
    BMC Musculoskelet Disord 9:72. 2008
    ....
  36. doi request reprint Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria
    Elke Geens
    Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium
    Rheumatology (Oxford) 48:546-50. 2009
    ..To assess discrepancies between perception of Belgian rheumatologists on eligibility of RA patients for anti-TNF treatment and Belgian reimbursement criteria and to compare Belgian with Dutch criteria and UK guidelines...
  37. doi request reprint Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis
    Lilian H D van Tuyl
    VU University Medical Center, Department of Rheumatology, De Boelelaan 1117, Amsterdam, The Netherlands
    Ann Rheum Dis 69:1623-8. 2010
    ....
  38. ncbi request reprint Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis
    Robert Landewe
    Department of Internal Medicine Rheumatology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands
    Arthritis Rheum 50:1390-9. 2004
    ....
  39. ncbi request reprint [Should the vitamin D level be determined for all fracture patients?]
    Joop van den Bergh
    Universitair Medisch Centrum Maastricht, afd Interne Geneeskunde, subdivisie Endocrinologie, Maastricht, The Netherlands
    Ned Tijdschr Geneeskd 154:A1758. 2010
    ....
  40. ncbi request reprint Analyses of immunosenescent markers in patients with autoimmune disease
    Marielle Thewissen
    Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Agoralaan, Diepenbeek, Belgium, and Department of Clinical and Experimental Immunology, University Hospital Maastricht, The Netherlands
    Clin Immunol 123:209-18. 2007
    ..Both genetic factors, such as HLA DR4, and environmental factors, like CMV infection, might speed up this immunosenescence and contribute in this way to disease pathogenesis...
  41. ncbi request reprint The fracture and osteoporosis outpatient clinic: an effective strategy for improving implementation of an osteoporosis guideline
    Svenhjalmar van Helden
    Department of General Surgery, Academic Hospital of Maastricht, Maastricht, The Netherlands
    J Eval Clin Pract 13:801-5. 2007
    ....
  42. doi request reprint Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
    Bert Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, B 9000 Gent, Belgium
    Rheumatology (Oxford) 49:73-81. 2010
    ..We aimed to describe the epidemiology of clinical and radiological hip involvement and define the risk factors for the hip replacement surgery in AS patients...
  43. ncbi request reprint Risk of new clinical fractures within 2 years following a fracture
    Svenhjalmar van Helden
    Department of Trauma Surgery, Academic Hospital Maastricht, P Debijelaan 25, Postal number 5800, 6202 AZ, Maastricht, The Netherlands
    Osteoporos Int 17:348-54. 2006
    ..The study objective was to determine the absolute risk of subsequent clinical fractures within 2 years after a clinical fracture...
  44. ncbi request reprint Regarding the article "low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study", by Kaptoge et al
    E Pijpers
    Bone 38:145; author reply 146-9. 2006
  45. ncbi request reprint [Clinical relevance of vertebral fractures]
    W F Lems
    VU Medisch Centrum, afd Reumatologie, 3A64, Postbus 7057, 1007 MB Amsterdam
    Ned Tijdschr Geneeskd 152:917-9. 2008
    ..The disadvantage of the poorer image quality, particularly in the higher thoracic region, is amply compensated for by the efficiency and diagnostic convenience to the patients and reduced exposure to radiation...